About Haemostatix
Haemostatix is a company based in Nottingham (United Kingdom) founded in 2003 was acquired by Ergomed in May 2016. Haemostatix has raised $2.43 million across 6 funding rounds from investors including University of Leicester, Royal Society of Chemistry and Albion Capital. The company has 11,995 employees as of December 31, 2020. Haemostatix operates in a competitive market with competitors including QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.
- Headquarter Nottingham, United Kingdom
- Employees 11995 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Haemostatix Limited
- Date of Incorporation 14 Mar, 2003
- Jurisdiction GUILDFORD, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
-$199.58 K (USD)69as on Dec 31, 2020
-
EBITDA
Not available
-
Total Equity Funding
$2.43 M (USD)
in 6 rounds
-
Latest Funding Round
$31.47 K (USD), Grant
Jun 29, 2015
-
Investors
University of Leicester
& 10 more
-
Employee Count
11995
as on Dec 31, 2020
-
Acquired by
Ergomed
(May 04, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Haemostatix
Haemostatix has successfully raised a total of $2.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $31.47 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Haemostatix
Haemostatix has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Leicester, Royal Society of Chemistry and Albion Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment solutions are provided by Catapult Ventures for growth.
|
Locked | Locked | Locked | |
|
Early-stage tech and life science investments are made in Europe.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Albion Capital.
|
Locked | Locked | Locked |
Investor details for Haemostatix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Haemostatix
Investment portfolio details for Haemostatix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Haemostatix
Detailed financials for Haemostatix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Haemostatix Comparisons
Peer comparison for Haemostatix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Haemostatix
Haemostatix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| Locked | Locked | Locked |
Powdered fibrin sealant for surgical bleeding
|
|
| Locked | Locked | Locked |
Topical formulations for corneal wounds, ulcers, and scars are developed.
|
Detailed competitors of Haemostatix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Haemostatix
Complete news archive for Haemostatix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Haemostatix
Haemostatix was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Haemostatix is headquartered in Nottingham, United Kingdom.
Haemostatix is a funded company, having raised a total of $2.43M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Haemostatix is 11,995.
Haemostatix has developed a new class of peptide-based coagulant, or haemostat, for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding. Haemostatixs pipeline includes PeproStat Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery; and HXP12 ReadyFlow, a flowable and transparent haemostatic gel that can be applied to irregular bleeding sites.
Haemostatix's top competitors include Ilya Pharma, QBiotics and Tempo Therapeutics.
Haemostatix has 11 investors. Key investors include University of Leicester, Royal Society of Chemistry, Albion Capital, Ergomed, and Catapult Ventures.